Financial Highlights – GSK PLC (LSE: GSK)

  • Q4 non-GAAP EPS of 26, beating estimates by 0.03
  • Revenue rose 3% YoY to USD 8.62 billion, ahead of forecasts
  • Strong cash generation with USD 8.9 billion operating cash flow and USD 4.0 billion free cash flow
  • Q4 dividend of 18p, taking FY payout to 66p; targeting 70p in 2026
  • USD 1.4 billion of the USD 2.0 billion share buyback already completed
  • 2026 outlook reaffirmed: turnover growth 3%–5%, core EPS growth 7%–9%
  • Long-term ambition unchanged: over USD 40 billion annual sales by 2031, led by Speciality Medicines.

GSK PLC (LSE: GSK)

GSK PLC rose sharply on 04 February 2026, climbing 6.91% to trade near GBX 2,080.00, after the company reported better-than-expected quarterly profit and outlined an early strategic reset under new chief executive Luke Miels. The update highlighted a sharper focus on accelerating research and development, disciplined acquisitions, and strengthening the pipeline ahead of an approaching patent cliff. Solid momentum in HIV treatments, the shingles vaccine, and respiratory medicines supported results, while management reaffirmed confidence in delivering steady profit growth despite currency-related headwinds.

GSK Delivers Earnings Beat as Cash Strength Supports Outlook

GSK PLC (LSE: GSK) delivered a reassuring quarter, exceeding expectations on sales and earnings while staying aligned with its longer-term strategy. Fourth-quarter non-GAAP EPS of 0.26 beat estimates, as revenue rose 6.3% year over year to 8.62 billion. Strong cash generation supported shareholder returns, with a Q4 dividend of 18p, bringing the full-year payout to 66p and setting expectations for 70p in 2026. Management reaffirmed its outlook for steady turnover growth and core EPS expansion.

Technical View: GSK Shares Extend Breakout as Momentum Accelerates Above Key Averages

From a technical perspective, GSK PLC (LSE: GSK) shares surged above recent consolidation to trade near GBX 2,080.00, reinforcing a strong broader structure. The price remains firmly above the 21-day and 50-day Simple Moving Averages, which continue to trend higher and provide underlying support. Momentum has strengthened, with the 14-day RSI near 77.15, reflecting elevated but sustained strength. Volumes expanded with the advance. Immediate support is seen around GBX 1,870.00 and GBX 1,700.00, while resistance is placed near GBX 2,300.00 and GBX 2,540.00.

Bottom Line: GSK at a 26-Year High — Is the Re-rating Sustainable?

GSK plc’s rally reflects strong earnings delivery, resilient cash flows, and confidence in its strategic reset. While near-term consolidation is possible after the sharp move, the broader structure remains constructive, with attention centred on pipeline execution and specialty medicines growth.